Navigation Links
VITAS Innovative Hospice Care(R) Names Christopher Rieder Senior Vice President and Chief Information Officer

MIAMI, Feb. 24 /PRNewswire/ -- VITAS Innovative Hospice Care(R) announced today that Christopher Rieder has been named senior vice president and chief information officer. In his new position, Rieder will oversee planning and implementation of IT operations throughout VITAS to support the company's strategic direction.

Rieder has more than 20 years of IT experience with global organizations translating business objectives into technology solutions. He has worked extensively with pharmaceutical and biotechnology companies.

Rieder most recently was chief information officer and vice president at Parexel, Inc., a leading bio-pharmaceutical services organization. At Parexel, Rieder led the company's worldwide technology initiatives, including integration of technology solutions, information management and business processes. Prior to that position, Rieder served as vice president of information technology for Kos Pharmaceuticals, where he built a customer- centric IT division to improve the company's customer service operations.

"Chris's experience at the senior management level will make him a superb asset to our organization," said David Wester, VITAS president and chief financial officer. "His ability to bring a working knowledge of technology to corporate initiatives will help us continue to offer innovative solutions for providing exceptional end-of-life care to our patients and their families."

Rieder holds an MBA in information technology from American University in Washington, D.C., and a BSBA in business economics and pre-medicine from the University of Arizona. A member of the Society for Information Management, Rieder was a contributing author of the book, "Improving Technology ROI: Leading CTOs and CIOs on Making Successful Technology Investments, Maximizing Return on Investments, & Gaining a Competitive Edge (Inside the Minds)."

VITAS Innovative Hospice Care(R), a pioneer and leader in the hospice movement since 1978, is one of the nation's largest providers of end-of-life care. Headquartered in Miami, Florida, VITAS (pronounced VEE-tahs) operates 45 hospice programs in 16 states (California, Connecticut, Delaware, District of Columbia, Florida, Georgia, Illinois, Kansas, Michigan, Missouri, New Jersey, Ohio, Pennsylvania, Texas, Virginia and Wisconsin). A wholly-owned subsidiary of Chemed Corporation (NYSE: CHE), VITAS employs 9,079 professionals who care for terminally ill patients daily, primarily in the patients' homes, but also in the company's 25 inpatient hospice units as well as in hospitals, nursing homes and assisted living communities/residential care facilities for the elderly. At the conclusion of the fourth quarter of 2008, VITAS reported an average daily census of 11,627.

SOURCE VITAS Innovative Hospice Care(R)
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Navitas Names Dr. Dean Gesme as Medical Director
2. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
3. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
4. CardioDynamics Receives FDA 510(k) Clearance for Innovative Clinical Parameters and Electronic Medical Record Compatibility
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features
7. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
8. Innovative Fosshield(R) Antimicrobial Technology Shown to Continuously Kill MRSA Superbug
9. Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
10. A&G Pharmaceutical Receives $870,000 Grant from Avon Foundation to Advance Innovative Blood Diagnostic Test for Early Detection of Breast Cancer
11. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... Connecticut (PRWEB) , ... June 23, 2016 , ... ... introduce a new line of intelligent tools designed, tuned and optimized exclusively for ... September 12–17 in Chicago. The result of a collaboration among several companies with ...
Breaking Biology Technology:
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
Breaking Biology News(10 mins):